Influence of dose rate on radiotherapy treatment of the U87MG cell line through cell viability
DOI:
https://doi.org/10.15392/2319-0612.2024.2621Keywords:
Glioblastoma multiforme, Radiotherapy, cell line, U87MG, dose rates, cell viability, MTTAbstract
Glioblastoma multiforme is a tumor that affects glial cells and is common in humans, being the most aggressive of gliomas. Patients, after diagnosis, have an average survival of just over a year, even when undergoing standard treatment. Given the low estimated survival of patients with this type of tumor, the objective of the study is to investigate the contribution of dose rate in radiotherapeutic treatment using a human glioblastoma cell line called U87MG, through the MTT (brometo de 3-[4,5-dimetiltiazol-2-il]-2,5-difenil tetrazólio) cell viability assay. Three dose rates were tested, including 400 cGy/min which is used clinically in patients, as well as 1.400 and 3.300 cGy/min from a clinical linear accelerator. Sterile culture plates with U87MG cells were irradiated, then, manipulated in the laboratory for the execution of the cell viability assay. The irradiated plates showed lower cell viability than the non-irradiated group, but there was no significant difference in viability among the different tested dose rates.
Downloads
References
[1] ALIFIERIS, Constantinos; TRAFALIS, Dimitrios T. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacology & therapeutics, v. 152, p. 63-82, 2015. DOI: https://doi.org/10.1016/j.pharmthera.2015.05.005
[2] WEN, Patrick Y.; KESARI, Santosh. Malignant gliomas in adults. New England Journal of Medicine, v. 359, n. 5, p. 492-507, 2008. DOI: https://doi.org/10.1056/NEJMra0708126
[3] CLOUGHESY, Timothy F.; CAVENEE, Webster K.; MISCHEL, Paul S. Glioblastoma: from molecular pathology to targeted treatment. Annual review of pathology: mechanisms of disease, v. 9, n. 1, p. 1-25, 2014. DOI: https://doi.org/10.1146/annurev-pathol-011110-130324
[4] BARANI, Igor J.; LARSON, David A. Radiation therapy of glioblastoma. Current understanding and treatment of gliomas, p. 49-73, 2015. DOI: https://doi.org/10.1007/978-3-319-12048-5_4
[5] CHÉDEVILLE, Agathe L.; MADUREIRA, Patricia A. The role of hypoxia in glioblastoma radiotherapy resistance. Cancers, v. 13, n. 3, p. 542, 2021. DOI: https://doi.org/10.3390/cancers13030542
[6] GHASEMI, Mahshid et al. The MTT assay: utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. International journal of molecular sciences, v. 22, n. 23, p. 12827, 2021. DOI: https://doi.org/10.3390/ijms222312827
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 Arthur Rocha, Ruy Rayol Neto, Debora Assis Carneiro, Delano Valdivino Batista, Luiz Antonio Ribeiro da Rosa, Mariana Paranhos Stelling, Simone Coutinho Cardoso
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
